Delcath Systems (DCTH) Stock Price
Delcath Systems Price
Over the last 13 years Delcath Systems grew revenue by 52.7% annually, reaching 85.23 M USD. For Delcath Systems, the net margin of 3.2% is up versus -721.5% a few years ago. The consensus 12-month price target for Delcath Systems is 27.00 USD, about 75.2% above where the stock trades today. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus.
Delcath Systems stock price
Delcath Systems business model & stock analysis
Frequently asked questions about Delcath Systems
Delcath Systems Inc is a medical technology company specializing in targeted therapies for the treatment of various forms of cancer. Their business model revolves around providing innovative solutions that enable physicians to safely deliver high doses of chemotherapeutic agents directly to the affected organs, while minimizing exposure to healthy tissues. Delcath Systems' proprietary system, known as Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Delcath HDS), offers significant advancements in cancer treatment by enhancing drug delivery precision and reducing systemic side effects. This targeted delivery approach holds immense potential in improving patient outcomes and is at the forefront of Delcath Systems' mission to revolutionize cancer treatment.
Delcath Systems Inc is primarily active in the fields of medical technology and healthcare.
The main competitors of Delcath Systems Inc in the market are Exact Sciences Corporation, Guardant Health Inc, Illumina Inc, and Veracyte Inc.
Delcath Systems Inc is a renowned biomedical technology company. Established in the late 1980s, Delcath Systems Inc specializes in the development and commercialization of innovative cancer treatments. The company's flagship product is the Delcath Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapy to the liver while minimizing systemic exposure. This targeted approach aids in improving treatment outcomes and reducing toxicities associated with traditional delivery methods. With a focus on advancing oncology therapies, Delcath Systems Inc is dedicated to enhancing the lives of patients worldwide.
Delcath Systems Inc, a leading medical technology company, has reached several significant milestones over the years. Notably, the company gained FDA approval for its innovative Chemostat System, allowing targeted chemotherapy delivery to the liver. Delcath also secured CE Mark certification, enabling commercialization in European markets. Furthermore, the company successfully conducted various clinical trials, showcasing the effectiveness of its technology in treating liver cancer and other hepatic diseases. Delcath Systems Inc's accomplishments highlight its commitment to advancing medical therapies and addressing critical needs in oncology.
Delcath Systems Inc is primarily present in the United States.
Delcath Systems Inc represents values of innovation, dedication, and commitment in the field of medical technology. The company's corporate philosophy revolves around delivering advanced solutions for the treatment of cancers, particularly liver cancers. With an emphasis on precision medicine, Delcath Systems Inc aims to provide personalized therapies that target tumors directly, while minimizing the impact on healthy tissues. By developing novel therapies, such as the CHEMOSAT® system, the company demonstrates its dedication to revolutionizing cancer treatment options. Delcath Systems Inc strives to make a positive impact on patients' lives by continuously pushing the boundaries of medical advancements in oncology.
Analysts currently set an average price target of 25.33 USD for the Delcath Systems stock (median: 27.00 USD), implying +64.4 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Delcath Systems stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Delcath Systems to generate revenue of 106.44 M USD and earnings per share of -0.13 USD.
Converted at the current exchange rate, the Delcath Systems share trades at 13.76 EUR (15.41 USD).
The Delcath Systems share (DCTH) is listed on 3 stock exchanges, including: NASDAQ (DCTH), Frankfurt (DV3R.F), München (DV3R.MU).
Delcath Systems Inc. is a US biopharmaceutical company specializing in the development and commercialization of innovative product solutions to improve the treatment of liver cancer. It is listed on the NASDAQ stock exchange.
The expected revenue of Delcath Systems is 106.44 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Delcath Systems is -5.13 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Delcath Systems is currently -119.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Delcath Systems stock.
The price-to-sales ratio (P/S) of Delcath Systems is currently 5.77. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Delcath Systems stock.
The Eulerpool Quality Score for Delcath Systems is 6/10.
The ISIN of Delcath Systems is US24661P8077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Delcath Systems is A2PT5P. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Delcath Systems is DCTH. The ticker symbol is used to trade Delcath Systems shares on the stock exchange.
Delcath Systems stock
Delcath Systems Peer Group
Delcath Systems Ticker
Delcath Systems FIGI
All fundamentals and in-depth analysis of Delcath Systems
Our stock analysis for Delcath Systems stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Delcath Systems. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.